期刊
JOURNAL OF BIOMOLECULAR SCREENING
卷 18, 期 3, 页码 298-308出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1087057112465647
关键词
high-throughput screening; inositol-requiring enzyme 1 alpha; DELFIA; multiple myeloma; XBP1; UPR
资金
- Cancer Research UK [C309/A8274, C20826/A12103]
- NHS
- Cancer Research UK [11566, 12103] Funding Source: researchfish
Inositol-requiring enzyme 1 alpha (IRE1 alpha) is a transmembrane sensor protein with both kinase and ribonuclease activity, which plays a crucial role in the unfolded protein response (UPR). Protein misfolding in the endoplasmic reticulum (ER) lumen triggers dimerization and subsequent trans-autophosphorylation of IRE1 alpha. This leads to the activation of its endoribonuclease (RNase) domain and splicing of the mRNA of the transcriptional activator XBP1, ultimately generating an active XBP1 (XBP1s) implicated in multiple myeloma survival. Previously, we have identified human IRE1 alpha as a target for the development of kinase inhibitors that could modulate the UPR in human cells, which has particular relevance for multiple myeloma and other secretory malignancies. Here we describe the development and validation of a 384-well high-throughput screening assay using DELFIA technology that is specific for IRE1 alpha autophosphorylation. Using this format, a focused library of 2312 potential kinase inhibitors was screened, and several novel IRE1 alpha kinase inhibitor scaffolds were identified that could potentially be developed toward new therapies to treat multiple myeloma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据